Risedronate sodium| CAS#115436-72-1 | 105462-24-6

Risedronate sodium
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 318668

CAS#: 115436-72-1 (sodium)

Description: Risedronate, also known as NE-58095, often used as its sodium salt risedronate sodium (USAN), is a bisphosphonate used to strengthen bone, treat or prevent osteoporosis, and treat Paget's disease of bone. Like other bisphosphonates, it inhibits bone resorption. In addition, it has antimalarial activity and inhibits growth of P. falciparum in vitro (IC50 = 20.3 µM) and P. berghei in vivo.

Chemical Structure

Risedronate sodium

CAS# 115436-72-1 (sodium)

Instruction

Theoretical Analysis

MedKoo Cat#: 318668
Name: Risedronate sodium
CAS#: 115436-72-1 (sodium)
Chemical Formula: C7H10NNaO7P2
Exact Mass: 283.00
Molecular Weight: 305.094
Elemental Analysis: C, 27.56; H, 3.30; N, 4.59; Na, 7.54; O, 36.71; P, 20.30

Price and Availability

Size	Price	Availability	Quantity
1g	USD 250
2g	USD 450
5g	USD 850
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Related CAS #: 105462-24-6 (free acid) 115436-72-1 (sodium)

Synonym: NE-58095; NE 58095; NE58095; Risedronate, Risedronic acid, Risedronate sodium, Actonel, Atelvia, Benet

IUPAC/Chemical Name: sodium hydrogen (1-hydroxy-1-phosphono-2-(pyridin-3-yl)ethyl)phosphonate

InChi Key: DRFDPXKCEWYIAW-UHFFFAOYSA-M

InChi Code: InChI=1S/C7H11NO7P2.Na/c9-7(16(10,11)12,17(13,14)15)4-6-2-1-3-8-5-6;/h1-3,5,9H,4H2,(H2,10,11,12)(H2,13,14,15);/q;+1/p-1

SMILES Code: OC(P(O)([O-])=O)(CC1=CC=CN=C1)P(O)(O)=O.[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info: Related CAS# CAS#115436-72-1 (Risedronate sodium) CAS#105462-24-6 (Risedronate free)

Certificate of Analysis:

View CoA: current batch, Lot#C21M08C26

Safety Data Sheet (SDS):

View Safety Data Sheet (SDS)

Instruction:

View handling instruction

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 305.09 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Quesada-Gómez JM, Santiago-Mora R, Navarro-Valverde C, Dorado G, Casado-Díaz A. Stimulation of in-vitro angiogenesis by low concentrations of risedronate is mitigated by 1,25-dihydroxyvitamin D3 or 24,25-dihydroxyvitamin D3. J Steroid Biochem Mol Biol. 2015 Apr;148:214-8. doi: 10.1016/j.jsbmb.2014.10.018. Epub 2014 Nov 1. Review. PubMed PMID: 25445918.

2: Nuti R. Updates on mechanism of action and clinical efficacy of risedronate in osteoporosis. Clin Cases Miner Bone Metab. 2014 Sep;11(3):208-14. Review. PubMed PMID: 25568655; PubMed Central PMCID: PMC4269145.

3: Hemmati I, Wade J, Kelsall J. Risedronate-associated scleritis: a case report and review of the literature. Clin Rheumatol. 2012 Sep;31(9):1403-5. doi: 10.1007/s10067-012-2035-z. Epub 2012 Aug 5. Review. PubMed PMID: 22864810.

4: In brief: delayed-release risedronate (Atelvia). Med Lett Drugs Ther. 2011 Mar 21;53(1360):24. Review. Erratum in: Med Lett Drugs Ther. 2011 Jun 27;53(1367):52. PubMed PMID: 21412209.

5: Iwamoto J, Takeda T, Sato Y, Matsumoto H. Effects of risedronate on osteoarthritis of the knee. Yonsei Med J. 2010 Mar;51(2):164-70. doi: 10.3349/ymj.2010.51.2.164. Epub 2010 Feb 12. Review. PubMed PMID: 20191005; PubMed Central PMCID: PMC2824859.

6: Epstein S, Jeglitsch M, McCloskey E. Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. Curr Med Res Opin. 2009 Dec;25(12):2951-60. doi: 10.1185/03007990903361307. Review. PubMed PMID: 19835464.

7: Hagino H. [Risedronate for treatment of osteoporosis]. Nihon Rinsho. 2009 May;67(5):948-53. Review. Japanese. PubMed PMID: 19432115.

8: Kishimoto H. [Efficacy and tolerability of risedronate for the treatment of osteoporosis]. Clin Calcium. 2008 Oct;18(10):1417-26. doi: CliCa081014171426. Review. Japanese. PubMed PMID: 18830038.

9: Wells G, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008 Jan 23;(1):CD004523. doi: 10.1002/14651858.CD004523.pub3. Review. PubMed PMID: 18254053.

10: Soen S. [Evidence of risedronate for treatment of osteoporosis]. Nihon Rinsho. 2007 Nov 28;65 Suppl 9:344-7. Review. Japanese. PubMed PMID: 18161128.

11: Bobba R, Adachi JD. Review of the safety and efficacy of risedronate for the treatment of male osteoporosis. Clin Interv Aging. 2007;2(3):275-82. Review. PubMed PMID: 18044178; PubMed Central PMCID: PMC2685258.

12: Takata S. [Therapeutic effects of risedronate on Paget's disease of bone]. Clin Calcium. 2006 Sep;16(9):1508-12. Review. Japanese. PubMed PMID: 16951476.

13: Recker RR, Barger-Lux J. Risedronate for prevention and treatment of osteoporosis in postmenopausal women. Expert Opin Pharmacother. 2005 Mar;6(3):465-77. Review. PubMed PMID: 15794737.

14: Fukunaga M. [VERT(Vertebral Efficacy with Risedronate Therapy)-MN(Multinational) Study and VERT-NA(North America) Study]. Nihon Rinsho. 2004 Feb;62 Suppl 2:433-6. Review. Japanese. PubMed PMID: 15035166.

15: Fukunaga M. [Risedronate]. Nihon Rinsho. 2003 Feb;61(2):235-9. Review. Japanese. PubMed PMID: 12638214.

16: Deal CL. Risedronate prevents hip fractures, but who should get therapy? Cleve Clin J Med. 2002 Dec;69(12):964, 968-70, 973-6. Review. PubMed PMID: 12546269.

17: Baker DE. Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity. Rev Gastroenterol Disord. 2002;2(1):20-33. Review. PubMed PMID: 12122976.

18: Viñas G, Olivé A, Holgado S, Costa J. [Episcleritis secondary to risedronate]. Med Clin (Barc). 2002 Apr 27;118(15):598-9. Review. Spanish. PubMed PMID: 12015954.

19: Sickels JM, Nip CS. Risedronate for the prevention of fractures in postmenopausal osteoporosis. Ann Pharmacother. 2002 Apr;36(4):664-70. Review. PubMed PMID: 11918518.

20: Dougherty JA. Risedronate for the prevention and treatment of corticosteroid-induced osteoporosis. Ann Pharmacother. 2002 Mar;36(3):512-6. Review. PubMed PMID: 11895066.

Your view history

Risedronate sodium featured